Exagen (XGN) Current Deferred Revenue (2024 - 2026)

Exagen has reported Current Deferred Revenue for 3 years, with the latest figure at $700000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 22.22% year-over-year to $700000.0; the trailing twelve-month figure through Mar 2026 stood at $700000.0 (down 22.22% YoY), and the FY2025 full-year result was $700000.0, down 4.5% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $700000.0, roughly flat from $700000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $1.0 million in Q2 2025, with the low at $600000.0 in Q3 2025.
• Historically, Current Deferred Revenue has averaged $772166.7 across 3 years, with a median of $716500.0 in 2024.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue slipped 4.5% — and 2026, when it declined 22.22%.
• Exagen's Current Deferred Revenue stood at $733000.0 in 2024, then declined by 4.5% to $700000.0 in 2025, then changed by 0.0% to $700000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $700000.0 (Q1 2026), $700000.0 (Q4 2025), and $600000.0 (Q3 2025), per Business Quant data.